Salix Pharmaceuticals, Ltd. - Strategy, SWOT and Corporate Finance Report
Salix Pharmaceuticals, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.
Detailed information on Salix Pharmaceuticals, Ltd. required for business and competitor intelligence needs
A study of the major internal and external factors affecting Salix Pharmaceuticals, Ltd. in the form of a SWOT analysis
An in-depth view of the business model of Salix Pharmaceuticals, Ltd. including a breakdown and examination of key business segments
Intelligence on Salix Pharmaceuticals, Ltd.’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
News about Salix Pharmaceuticals, Ltd., such as business expansion, restructuring, and contract wins
Large number of easy-to-grasp charts and graphs that present important data and key trends
Reasons To Buy
Gain understanding of Salix Pharmaceuticals, Ltd. and the factors that influence its strategies
Track strategic initiatives of the company and latest corporate news and actions
Assess Salix Pharmaceuticals, Ltd. as a prospective partner, vendor or supplier
Support sales activities by understanding your customers' businesses better
Stay up to date on Salix Pharmaceuticals, Ltd.’s business structure, strategy and prospects
Salix Pharmaceuticals (Salix or 'the company') is a specialty pharmaceutical company engaged in the acquisition, development and commercialization of prescription pharmaceutical products for the treatment of gastrointestinal diseases. The company's marketed drugs include Xifaxan, Osmoprep and Metozolv ODT. Salix primarily operates in the US, where it is headquartered in Raleigh, North Carolina. It employed about 1,000 people as of December 31, 2014.